Austedo

Active Ingredient(s): Deutetrabenazine
FDA Approved: * April 3, 2017
Pharm Company: * TEVA PHARMS USA INC
Category: Neurological Disorders

Deutetrabenazine (trade name Austedo) is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia. Chemically, deutetrabenazine is an isotopic isomer of tetrabenazine in which six hydrogen atoms have been replaced by deuterium atoms. The incorporation of deuterium slows the rate of drug metabolism, allowing less frequent dosing.[2][3] Contents 1 Efficacy 2 Pharma... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Austedo 6 mg Oral Tablet, Coated
NDC: 68546-170
Labeler:
Teva Neuroscience, Inc.
Austedo 9 mg Oral Tablet, Coated
NDC: 68546-171
Labeler:
Teva Neuroscience, Inc.
Austedo 12 mg Oral Tablet, Coated
NDC: 68546-172
Labeler:
Teva Neuroscience, Inc.
AustedoAustedo Kit
NDC: 68546-176
Labeler:
Teva Neuroscience, Inc.
AustedoAustedo Kit
NDC: 68546-177
Labeler:
Teva Neuroscience, Inc.
AustedoAustedo Kit
NDC: 68546-181
Labeler:
Teva Neuroscience, Inc.
AustedoAustedo Kit
NDC: 68546-182
Labeler:
Teva Neuroscience, Inc.